Cinacalcet
From Wikipedia, the free encyclopedia
 |
|
|
Cinacalcet
|
|
| Systematic (IUPAC) name | |
| N-[(1R)-1-(1-naphthyl)ethyl]-3- [3-(trifluoromethyl)phenyl]propan-1-amine |
|
| Identifiers | |
| CAS number | 226256-56-0 |
| ATC code | H05BX01 |
| PubChem | 156419 |
| DrugBank | APRD00872 |
| Chemical data | |
| Formula | C22H22NF3 |
| Mol. weight | 357.412 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 20 to 25% Increases if taken with food |
| Protein binding | 93 to 97% |
| Metabolism | Hepatic (CYP3A4-, CYP2D6- and CYP1A2-mediated) |
| Half life | 30 to 40 hours |
| Excretion | Renal (80%) and fecal (15%) |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. | |
| Legal status |
℞ Prescription only |
| Routes | Oral |
Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues). It is sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure.
[edit] External links
- Cinacalcet - Medlineplus.org
- Cinacalcet - Drug Digest.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
